STAT+: Under protest, FDA to convene advisory panel to review controversial cell therapy for ALS
The Food and Drug Administration will convene a meeting of independent advisers to review a…
Category: STAT+
STAT+: Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the stakes
For the past two months, the health insurance industry has attempted to scare older adults…
STAT+: Pharmalittle: EU delays pharma legislation again; India cancels license for maker of cough syrup linked to deaths
And so, another working week will soon draw to a close. Not a moment too…
.jpg)
STAT+: J&J loses a patent battle in India over a crucial tuberculosis drug
In a defeat for Johnson & Johnson, the Indian patent office has rejected its bid…
STAT+: Pharmalittle: FDA panel backs conditional approval for Biogen ALS drug; pharma fights tactic for lowering specialty med costs
Rise and shine, everyone, another busy day is on the way. This morning is getting…
STAT+: Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’ ‘massive payouts’ to execs
WASHINGTON — Sens. Elizabeth Warren (D-Mass.) and Jeff Merkley (D-Ore.) slammed seven different Medicare Advantage…
STAT+: FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS
An independent panel of advisors to the Food and Drug Administration on Wednesday concluded that…
STAT+: Drugmakers push back on a clever tactic employers use to avoid paying for specialty medicines
In the face of rising drug prices, health plan sponsors have quietly used a clever,…
STAT+: Senators interrogate health secretary Becerra on Alzheimer’s drug coverage
WASHINGTON — The future of Alzheimer’s treatments and coverage hung heavily over lawmakers’ Wednesday hearing…
STAT+: Researchers devise new strategies to overcome a key CRISPR flaw
DALLAS — It took just three years, after the tool’s invention, for researchers to devise…
STAT+: Once a Silicon Valley darling, Mindstrong sells its mental health technology for parts
SAN FRANCISCO — Mindstrong, a high-profile mental health tech startup, is selling off its assets…
STAT+: Pharmalittle: U.K. regulator to streamline clinical trial approvals; NIH won’t seize patents to cut price of cancer drug
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: NIH rejects bid to cut a cancer drug’s price by sidestepping patents
In a long-awaited decision, the U.S. National Institutes of Health rejected a petition urging the…
STAT+: 89bio treatment reduces liver scarring in patients with NASH, meeting study goals
89bio said Wednesday that its experimental treatment improved liver scarring at more than three times…
STAT+: Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal
More than 200 civil society and patient advocacy groups are urging the U.K. government to…
STAT+: Altimmune’s obesity drug fails to stand out from blockbuster treatments in early data
A new obesity treatment being developed by Altimmune met goals for weight loss in a…
STAT+: Pharmalittle: FDA official wants to use accelerated approval for gene therapies; pharma asks Biden for tax breaks in the semiconductor package
Top of the morning to you, and a fine one it is. A bright, shiny…
STAT+: A new Medicare ruling could give virtual reality companies an easier path to payment
The path to payment for virtual reality companies working in health care just became slightly…
STAT+: 8 burning questions Bernie Sanders and other senators should ask Moderna’s Stéphane Bancel
WASHINGTON — Moderna CEO Stéphane Bancel has some explaining to do. Bancel will appear alone…
STAT+: Senator calls for probe of conflict of interest on federal panel overseeing dietary guidelines
A U.S. lawmaker wants the federal government to probe potential conflicts of interest held by…
.jpg)
STAT+: Top FDA official: Agency needs to start using accelerated approval for gene therapies
DALLAS — A top Food and Drug Administration official said Monday that the agency needs…
STAT+: Pharmalittle: Manufacturers say bird flu shots for humans can be made quickly; obesity guidelines for children disappoint
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: ‘We’re getting much more aggressive’: Microsoft’s Nuance adds GPT-4 AI to its medical note-taking tool
An AI medical scribe platform is the latest entrant into the AI arms race. On…
STAT+: Karuna’s treatment for schizophrenia achieves study goals, bolsters FDA filing plans
Karuna Therapeutics said Monday that its treatment for schizophrenia reduced psychosis reported by patients —…
STAT+: Hospitals are not crumbling, Medicare experts tell Congress
Hospitals’ financial situations are not nearly as dire as industry groups are making them out…
STAT+: Takeda autoimmune therapy shows effectiveness in key trial
Doctors and investors are getting their first glimpse of the data that compelled Takeda Pharmaceutical…
STAT+: Moderna CEO made $398 million in 2022, but still pledges to give most to charity
Moderna CEO Stéphane Bancel is starting to reap gargantuan gains from the stock he first…
STAT+: Pharmalittle: Sanofi cuts price on a popular insulin by 78%; Califf criticizes insurers for doing too little on drug research
And so, another working week will soon draw to a close. Not a moment too…
STAT+: To prevent emergency C-sections, researchers turn to AI to predict the course of childbirth
After more than a decade as an OB-GYN, Darine El-Chaâr still finds late-stage emergency C-sections…
STAT+: Federal Medicaid officials cajole states to auto-enroll beneficiaries as huge coverage losses loom
WASHINGTON — Federal Medicaid officials are working unusually closely with states to avoid enrollment glitches…
STAT+: FDA to convene advisory panel for Sarepta’s gene therapy for Duchenne
In a sudden about-face, the Food and Drug Administration will hold a meeting of outside…
STAT+: Sanofi becomes the third leading insulin maker to lower list prices, cutting Lantus price by 78%
Following the lead of its rivals, Sanofi will cut the price of its most widely…
STAT+: Here’s why there aren’t many cheap, generic versions of pricey inhalers
U.S. regulators approved dozens of inhalers to treat asthma and chronic obstructive pulmonary disease over…
STAT+: Califf criticizes insurers for doing too little on drug research
WASHINGTON — FDA Commissioner Robert Califf wants private insurers to chip in on doing post-approval…
STAT+: Pharmalittle: Alzheimer’s group starts lobbying for Medicare to cover new drug; U.S. judge seems sympathetic to abortion-pill challenge
Good morning, everyone, and how are you today? Hazy skies are enveloping the frosty Pharmalot…
STAT+: U.K. trade group suspends Novo Nordisk for ‘serious breaches’ in promoting obesity drug
In a rare move, a U.K. pharmaceutical industry trade group suspended Novo Nordisk for two…
STAT+: CRISPR? Nah. A new startup bets on an old approach to gene editing
Before there was CRISPR, aspiring genome editors relied on an island of misfit, less elegantly…
STAT+: Momentum grows to subject medical devices to medicine’s gold standard — the placebo treatment
It’s the gold standard in medicine: taking a treatment, and putting it head-to-head against a…
STAT+: The big-money Medicare policy that has hospitals worried this Congress
WASHINGTON — There are few things that get lawmakers in Washington salivating more than a wonky…
STAT+: Medicare explains how it will choose drugs for negotiation
WASHINGTON — Medicare laid out Thursday in the greatest detail yet how it will choose…
STAT+: Would the federal government defer to states to regulate PBMs?
WASHINGTON — After years of struggling to regulate the drug middlemen that create pharmacy networks,…
STAT+: Pharmalittle: Biden administration to fine drugmakers for price hikes on 27 meds; Dems push pharmacy chains over access to abortion pill
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: White House chooses a location for ARPA-H — sort of
WASHINGTON — Officials at the Advanced Research Projects Agency for Health are moving ahead with…
STAT+: Biden administration to fine manufacturers of 27 medicines for price hikes
WASHINGTON — The Biden administration will fine drugmakers who hiked prices faster than the rate…
STAT+: In Minnesota, researchers explore how to audit health AI models on a patient level
As hospitals and companies continue to leverage artificial intelligence in medicine, researchers are also grappling…
STAT+: Democratic lawmakers press pharmacy chains on abortion pill access
More than a dozen Democratic lawmakers are urging some of the nation’s largest drugstore chains…
STAT+: PhRMA chief dings health insurers over drug prices at their own conference
WASHINGTON — The head of the brand drug lobby used an in-person health insurance industry…
STAT+: Amylyx’s ALS drug launch starts strong. That could be trouble for the FDA
Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question:…
STAT+: Pharmalittle: Novo to cut some insulin prices by up to 75%; Veterans Administration to cover new Alzheimer’s treatment
Rise and shine, everyone, another busy day is on the way. The Pharmalot campus, in…
STAT+: Novo Nordisk to lower insulin prices by up to 75% amid growing pressure
Under mounting pressure, Novo Nordisk plans to cut U.S. list prices for several insulin products…